Last --
Change Today 0.00 / 0.00%
Volume 0.0
PFZ On Other Exchanges
New York
SIX Swiss Ex
Sao Paulo
All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PFIZER INC (PFZ)

pfizer inc (PFZ) Details

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops, registers, and commercializes medicines for various therapeutic areas, including inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases, and women’s/men’s health. The VOC segment develops and commercializes vaccines, as well as products for oncology. It also provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control brand; respiratory products under the brand names of Robitussin, Advil Cold & Sinus, Advil Congestion Relief, and Dimetapp; and personal care products under the ChapStick and Preparation H brands. The GEP segment offers patent-protected products that have lost marketing exclusivity in various markets; and generic pharmaceuticals, and sterile injectable and biosimilar development products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

78,300 Employees
Last Reported Date: 02/27/15
Founded in 1849

pfizer inc (PFZ) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.2M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.1M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $926.3K
Group President of Global Established Pharma ...
Total Annual Compensation: $810.1K
Compensation as of Fiscal Year 2013.

pfizer inc (PFZ) Key Developments

Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

Pfizer Inc. announced that the European Commission approved an expanded indication for the use of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) for the prevention of pneumonia caused by the 13 pneumococcal serotypes in the vaccine in adults aged 18 years and older. The Summary of Product Characteristics has also been updated to include efficacy data from Pfizer’s landmark Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), which demonstrated statistically significant reductions in first episodes of vaccine-type pneumococcal community-acquired pneumonia (CAP), including non-invasive/non-bacteremic CAP, and invasive pneumococcal disease (IPD) in adults aged 65 and older.

Pfizer Inc. Announces Positive Results of Phase 2 Study Of TRUMENBA® (Meningococcal Group B Vaccine) Co-Administered with Routine Meningococcal (A, C, Y, and W) and Tetanus, Diptheria and Pertussis (Tdap) Vaccines in Adolescents

Pfizer Inc. announced positive results of a Phase 2 study of TRUMENBA® (Meningococcal Group B Vaccine) co-administered with FDA-approved, routine meningococcal (groups A, C, Y and W) (MCV4) and single-dose tetanus, diptheria and pertussis (Tdap) vaccines in more than 2,600 healthy individuals 10 through 12 years of age. The study met its co-primary immunogenicity objectives regarding co-administration of TRUMENBA with MCV4 and Tdap vaccines. In addition, data from a recently completed Phase 3 study demonstrated the safety and tolerability of TRUMENBA in approximately 5,600 healthy individuals 10 through 25 years of age, and were consistent with data from studies that supported the October 2014 accelerated approval of TRUMENBA in the United States. Phase 2 Study Design: Vaccine safety, tolerability and immunogenicity were evaluated in this Phase 2, randomized, controlled, observer-blinded study of TRUMENBA® in the U.S. The study included more than 2,600 healthy individuals 10 through 12 years of age. Group 1 received TRUMENBA co-administered with MCV4 and Tdap vaccines; Group 2 received MCV4 and Tdap vaccines only; and Group 3 received TRUMENBA only. Co-primary objectives included: Demonstration that the immune response induced by MCV4 and Tdap vaccines given with TRUMENBA was noninferior to the immune response induced by MCV4 and Tdap vaccines alone when measured one month after the first vaccination; and Demonstration that the immune response induced by TRUMENBA given with MCV4 and Tdap vaccines was noninferior to the immune response induced by TRUMENBA alone, when measured one month after the third vaccination with TRUMENBA. Phase 3 Study Design: Vaccine safety and tolerability were evaluated in this Phase 3, randomized, controlled, double-blind study of TRUMENBA® in the U.S., Europe, Australia and Chile. The study, which was initiated in November 2012, included approximately 5,600 healthy individuals assigned in a 2:1 ratio to receive TRUMENBA in a 0, 2, 6 month schedule or control. The control group received a licensed hepatitis A vaccine at month 0 and 6 and saline at month 2. Subjects were followed for six (6) months after the last vaccination to assess safety and tolerability. Primary endpoints included: the percentage of individuals with one or more serious adverse event from the first study vaccination through six (6) months after the last study vaccination; and the percentage of individuals with one or more medically-attended adverse event within 30 days after each vaccination (at 1, 3 and 7 months). The rate of adverse events following vaccination with TRUMENBA was compared to those occurring in the control group. U.S. Indication for TRUMENBA® (Meningococcal Group B Vaccine): TRUMENBA® (Meningococcal Group B Vaccine) is indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. Approval of TRUMENBA is based on the demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of TRUMENBA against diverse serogroup B strains has not been confirmed.

Pfizer Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015

Pfizer Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Presentation Date & Speakers: Feb-23-2015, Claudio Carini, Global Clinical Immunology and Biomarkers Lead, Greg Naeve, Head of Strategic Research Partnerships, Oncology, Leigh Zawel, Site Head, New York and Boston Centers for Therapeutic Innovation.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFZ:LN $0.00 USD 0.00

PFZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $57.98 USD +0.10
Nestle SA SFr.75.85 CHF +0.45
Novartis AG SFr.96.30 CHF +1.10
Roche Holding AG SFr.256.10 CHF -4.10
Procter & Gamble Co/The $84.49 USD +0.135
View Industry Companies

Industry Analysis


Industry Average

Valuation PFZ Industry Range
Price/Earnings 24.4x
Price/Sales 4.4x
Price/Book 3.1x
Price/Cash Flow 16.1x
TEV/Sales 2.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at